Training improves glaucoma-induced visual field defects
March 5th 2014Repetitive activation of residual vision with training of the visual field borders and areas of residual vision can improve visual field defects caused by glaucoma and increase detection sensitivity, according to results from a randomized clinical trial.
Ranibizumab may improve retinal function and structure in DME
February 28th 2014Treatment of diabetic macular oedema (DME) with ranibizumab may improve retinal function and structure, according to researchers from the National Institute for Health Research Biomedical Research Centre at Moorfields Eye Hospital and University College, London Institute of Ophthalmology.
Microbiological spectrum of post-traumatic endophthalmitis unchanged
February 27th 2014The microbiological spectrum in patients with post-traumatic endophthalmitis has remained unchanged over the past 14 years, with Bacillus spp. still the most commonly found infecting organism, and vancomycin remaining the drug of choice for empiric coverage of gram-positive bacteria.
New lenses show promise for sustained glaucoma treatment
February 26th 2014Researchers at University of California, Los Angeles, USA, have developed a new delivery system for treating patients with glaucoma. They have combined nanodiamonds - a by-product of conventional mining and refining processes - with timolol maleate into contact lenses that deliver sustained doses.
Fluocinolone acetonide for DME accepted by NHS Scotland
February 21st 2014The SMC has accepted fluocinolone acetonide (Iluvien, Alimera Sciences Inc.) - the only sustained-release treatment for chronic DME - for restricted use within the NHS Scotland after completing an assessment and review of a simple patient access scheme.
New surgical technique is effective for keratoconus
February 12th 2014For the management of keratoconus, diamond-knife?assisted DALK is effective and predictable in patients with keratoconus, and may offer visual and refractive outcomes that are similar to those achieved with big-bubble DALK, according to a recently published study.
Integrated laser platform receives CE Mark approval
February 7th 2014The Optimis Fusion integrated laser platform from Quantel Medical has received CE Mark approval. The system is a combination of advanced selective laser trabeculoplasty photoregeneration therapy with traditional YAG photodisruption treatment for treating both cataract and glaucoma.
Pre-op assessment should consider interactions between demographic and ocular factors
February 6th 2014Corneal refractive surgery may be more successful in eyes in which the cylinder mainly originates from the anterior cornea; therefore, in candidates for refractive surgery, surgeons should carefully assess the interaction between topographic, refractive and ocular residual astigmatism (ORA) to identify those at high risk for having significant differences between subjective cylinder and topographic astigmatism.
Retinal oxygen metabolism differs in glaucoma patients
February 5th 2014Patients with advanced glaucoma have higher oxygen saturation in venules and lower arteriovenous difference in oxygen saturation compared with healthy individuals. The decrease in arteriovenous difference in patients with severe glaucoma may be related to lower oxygen consumption secondary to neuropathy
Rebound tonometer comparable to Goldmann applanation
January 23rd 2014IOP measurements obtained with the rebound tonometer (Icare Pro) are more comparable to those achieved with the Goldmann applanation tonometer than those obtained with ultra-high-speed Scheimpflug technology, according to a recent study.
Combination procedure offers many advantages
January 17th 2014The combination of sutureless coaxial microincision cataract surgery and 23-gauge vitrectomy confers many advantages, including less wound leakage, good anterior chamber stability, safety, decreased inflammation and faster rehabilitation after surgery, according to the authors of a study published recently in Retina: The Journal of Retinal and Vitreous Diseases.
CXL therapy benefits patients with progressive keratoconus
January 10th 2014Collagen crosslinking (CXL) in patients with progressive keratoconus was found to be effective after 2 years in improving uncorrected distance visual acuity (UDVA), corrected distance visual acuity (CDVA), topographic metrics, and most corneal higher-order aberrations, according to a study published in Cornea: The Journal of Cornea and External Disease. Researchers noted that there was a significant reduction in apical keratometry, which directly correlated with improvements in visual acuity